Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients

HOUSTON, Nov. 19, 2019 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it now has preliminary data from its clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma (“CTCL”), which was published in Blood in conjunction with the American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019.

The release as fetched from its publisher. moleculin.com ↗